Valley wants our patients and community to be on the alert against medical billing scams. Learn how to protect yourself and your personal information from scammers posing as hospital representatives.Read More
MD, Rutgers University, Piscataway Campus, 1997 - 2001
BA, Rutgers University, 1992 - 1996
St. Vincent's Hospital And Medical Center, Cardiovascular Diseases, 2004 - 2007
- Internship & Residency
Robert Wood Johnson University Hospital, Internal Medicine, 2001 - 2004
- Board Certifications
American Board Of Internal Medicine - Certified, 2004
Subspecialty Board Of Cardiovascular Disease - Certified, 2007
Subspecialty Board Of Nuclear Cardiology - Certified, 2006
Get to Know Me
What are some of the specific conditions you treat?
Congestive heart failure, hypertension (high blood pressure), coronary artery disease, rhythm disorders, valvular heart disease.
What techniques or procedures do you use in your practice?
Exercise stress testing, nuclear imaging, ultrasound/echocardiography, including transesophageal.
What would you like patients to know about your approach to care?
I take pride in providing compassionate, personalized care to the adult cardiology patient, and making him or her feel comfortable with me as I address his or her needs.
Awards & Accolades
Castle Connolly Top Doctor New York Metro Area
Inside Jersey Magazine Top Doctors
Inside Jersey Magazine
Publications & Research
Epicardial Surgical Ligation of the Left Atrial Appendage Is Safe, Reproducible, and Effective by Transesophageal Echocardiographic Follow-up
The Amino Terminus of Cdk2 Binds p21
Pfizer 22 and Pfizer 38
Tests whether losmapimod, a new anti-inflammatory medication, can safely reduce the risk of a subsequent cardiovascular event (such as death, heart attack, or near heart attack requiring urgent treatment ) when started immediately after a heart attack.
Patients with non-valvular atrial fibrillation at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events.
Test the hypothesis that treatment with canakinumab will prevent recurrent cardiovascular events.
Compare a new agent, LCZ696, to valsartan in reducing the rate of cardiovascular death and heart failure hospitalizations, in heart failure patients with preserved ejection fraction (left ventricular ejection fraction ≥45%)
Valley Medical Group providers accept the following plans.
Patient Ratings & Comments
Comments are gathered from our patient satisfaction surveys.